Arrowhead Insiders Sold at $87; UBS Now Targets $109
Arrowhead Pharmaceuticals' interim Alzheimer's data showed 73% mean CSF tau reduction at Day 105, prompting UBS to raise its price target to $109 on October 15. The stock now trades at $58.50, well be
Arrowhead's Alzheimer Data Sends UBS to $109
NEW YORK, October 16 —
Two board directors sold Arrowhead Pharmaceuticals, Inc. (ARWR) at roughly $87 in August; the stock now trades at $58.50 after interim Alzheimer's data that prompted UBS to raise its price target to $109 the following day. The contradiction is the story: insiders with the deepest view of the pipeline chose to exit at a price the market has since abandoned, while analysts citing the same pipeline now see 80-plus percent upside from here.
- 85% peak CSF tau reduction at the 12.8 mg/kg dose; 73% mean reduction at Day 105, 90 days post-final-dose [news7]
- UBS raised its price target from $63 to $109 on October 15, maintaining Buy; mean analyst consensus sits at $107.36 [news8]
- Directors Perry and Olukotun sold a combined $1.19 million at ~$87/share on August 18, 2026, a 49% premium to today's price
What the tau numbers actually mean
Arrowhead Pharmaceuticals develops RNA interference therapeutics, drugs that silence disease-causing genes rather than blocking their protein products, and has no approved products on the market. ARO-MAPT is designed to silence the MAPT gene that encodes tau, the protein whose accumulation is a hallmark of Alzheimer's disease. The 73% mean CSF tau reduction measured at Day 105 matters not just for its magnitude but its timing: that readout came 90 days after the last dose, which Arrowhead cited as supporting a once-every-three-months dosing schedule. No serious treatment-emergent adverse events were observed in Part 1a. For a pre-revenue biotech whose 711-person workforce is entirely burning toward future milestones, clean tolerability data is as important as efficacy.
The selling pattern insiders left behind
Director Michael S. Perry sold 11,600 shares at $87.30 on August 18 for proceeds of $1,012,680; Director Adeoye Y. Olukotun sold 2,000 shares the same day at $86.96 for $173,920. Combined, roughly $1.19 million exited near $87, a price 49% above where ARWR trades today. Neither sale came after the ARO-MAPT interim readout; both preceded it by eight weeks. The stock gained on the October 14 data release and UBS promptly raised its target from $63 to that level. The question the August filings force is whether Perry and Olukotun were trimming opportunistically near a high, or whether the CNS data has genuinely shifted the pipeline's probability-weighted value in ways the August sellers could not have anticipated.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ARWR | $8.2B | n/a | +58.9% |
| ALNY | $31.3B | 18.8x | -51.4% |
| IONS | $7.3B | n/a | -39.6% |
| AXSM | $8.5B | 40.1x | +26.5% |
| ACAD | $3.4B | 21.4x | -5.6% |
| SRPT | $1.9B | 7.4x | -21.0% |
What changes the thesis
Arrowhead's balance sheet provides cover for patience: $1.60 billion in cash against $1.38 billion in debt, and milestone and licensing revenue from GlaxoSmithKline, Takeda, Amgen, and Sarepta running at $670 million trailing-twelve-months on 100% gross margins. Free cash flow was negative $49 million, a manageable burn. The Phase 1/2a study enrolls healthy volunteers first, then up to 48 subjects with early Alzheimer's disease; conviction requires those patient-cohort readouts, not yet available. A mean analyst target of $107.36 against a $58.50 price is either a substantial opportunity or a consensus that has yet to price in how difficult late-stage CNS trials tend to be. The number that settles it is the tau reduction in actual Alzheimer's patients, and that data does not exist yet. Run the free Arrowhead Pharmaceuticals, Inc. deep-dive →
Current fundamentals, valuation and filing history for Arrowhead Pharmaceuticals, Inc. (ARWR) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What tau reduction did Arrowhead's ARO-MAPT achieve?
ARO-MAPT showed 85% peak CSF tau reduction at the 12.8 mg/kg dose and 73% mean reduction at Day 105, measured 90 days after the final dose. The clean tolerability profile with no serious adverse events supports a once-every-three-months dosing schedule, which is clinically significant for an Alzheimer's treatment.
Why did board directors sell Arrowhead stock before the data?
Directors Perry and Olukotun sold a combined $1.19 million at approximately $87 per share on August 18, eight weeks before the tau data released. The article raises the question of whether they were trimming opportunistically at a high or whether they could not have anticipated how the interim data would shift the pipeline's probability-weighted value.
What is UBS's price target for Arrowhead after the tau data?
UBS raised its price target from $63 to $109 on October 15, the day after the data release. Mean analyst consensus is $107.36, representing 80-plus percent upside from the current stock price of $58.50.
How is Arrowhead's financial position?
Arrowhead has $1.60 billion in cash versus $1.38 billion in debt, with milestone and licensing revenue from major partners running at $670 million trailing-twelve-month on 100% gross margins. The company's free cash flow was negative $49 million, a manageable burn for its 711-person workforce.
When will we see data on actual Alzheimer's patients?
The Phase 1/2a trial enrolls healthy volunteers first, then up to 48 subjects with early Alzheimer's disease; those patient-cohort readouts are not yet available. The key data that will settle the investment thesis is tau reduction in actual Alzheimer's patients.
Arrowhead Pharmaceuticals reported an 85% peak reduction in cerebrospinal fluid tau from its ARO-MAPT Alzheimer's candidate on October 14, prompting UBS to nearly double its price target to $109 the following day — yet the stock at $58.50 sits well below the price two board directors were willing to sell just eight weeks ago.